Unionlab was established in 2017. Our founders had experiences in the full chain operation of new drug development from early R&D to commercialization, giving us a shared vision with our clients. Driven by clinical needs, Unionlab is dedicated to help clients plan and integrate resources to achieve success. We have 9 professional service modules aiming to accelerate the clinical studies while reducing costs. We deliver end-to-end full process services from strategy to execution to sponsors, and provide clinical study sites with digital solutions and exclusive CRC teams. Clinical trials of new drugs in the fields of oncology, infectious diseases and autoimmunity, relying on clinical research networks, Unionlab is capable of offering integrated full process services, facilitated by the in-house developed digital systems and tools. Our value creation is customer experience-oriented. We develop and leverage digital systems/tools and new methodology to accelerate new drug approvals and marketing. We build close collaboration with study site to achieve maximum efficiency of clinical studies from the starting point. Unionlab has over 600 employees based in more than 25 cities across China to provide services for over two hundred clinical trials of new drugs. In pursuit of our mission—"speeding up the clinical development of new drugs and benefit thousands of patients", we strive to be become the preferred partner for clinical development of novel cancer therapeutics.